Literature DB >> 25120735

Immune cells in primary and metastatic gastrointestinal stromal tumors (GIST).

Silke Cameron1, Marieke Gieselmann1, Martina Blaschke1, Giuliano Ramadori1, Laszlo Füzesi2.   

Abstract

We have previously described immune cells in untreated primary gastrointestinal stromal tumors (GIST). Here we compare immune cells in metastatic and primary GIST, and describe their chemoattractants. For this purpose, tissue microarrays from 196 patients, 188 primary and 51 metastasized GIST were constructed for paraffin staining. Quantitative analysis was performed for cells of macrophage lineage (Ki-M1P, CD68), T-cells (CD3, CD56) and B-cells (CD20). Chemokine gene-expression was evaluated by real-time RT-PCR. Immuno-localisation was verified by immunofluorescence. Ki-M1P+ cells were the predominant immune cells in both primary and metastatic GIST (2 8.8% ± 7.1, vs. 26.7% ± 6.3). CD68+ macrophages were significantly fewer, with no significant difference between primary GIST (3.6% ± 2.1) and metastases (4.6% ± 1.5). CD3+ T-cells were the most dominant lymphocytes with a significant increase in metastases (7.3% ± 2.3 vs. 2.2% ± 1.8 in primary GIST, P < 0.01). The percentage of CD56+ NK-cells was 1.1% ± 0.9 in the primary, and 2.4 ± 0.7 (P < 0.05) in the metastases. The number of CD20+ B-cells was generally low with 0.6% ± 0.7 in the primary and 1.8% ± 0.3 (P < 0.05) in the metastases. Analysis of the metastases showed significantly more Ki-M1P+ cells in peritoneal metastases (31.8% ± 7.4 vs. 18.2% ± 3.7, P < 0.01), whilst CD3+ T-cells were more common in liver metastases (11.7% ± 1.8 vs. 4.4% ± 2.6, P < 0.01). The highest transcript expression was seen for monocyte chemotactic protein 1 (MCP1/CCL2), macrophage inflammatory protein 1α (MIP-1α/CCL3) and the pro-angiogenic growth-related oncoprotein 1 (Gro-α/CXCL-1). Whilst the ligands were predominantly expressed in tumor cells, their receptors were mostly present in immune cells. This locally specific microenvironment might influence neoplastic progression of GIST at the different metastatic sites.

Entities:  

Keywords:  Gastrointestinal stromal tumor (GIST); immune cells; liver metastasis; microenvironment; peritoneal metastasis

Mesh:

Year:  2014        PMID: 25120735      PMCID: PMC4128970     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  85 in total

1.  Differential immobilization and hierarchical involvement of chemokines in monocyte arrest and transmigration on inflamed endothelium in shear flow.

Authors:  K S Weber; P von Hundelshausen; I Clark-Lewis; P C Weber; C Weber
Journal:  Eur J Immunol       Date:  1999-02       Impact factor: 5.532

2.  Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors.

Authors:  Florian Haller; Bastian Gunawan; Anja von Heydebreck; Stefanie Schwager; Hans-Jürgen Schulten; Judith Wolf-Salgó; Claus Langer; Giuliano Ramadori; Holger Sültmann; László Füzesi
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

3.  Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients.

Authors:  Cédric Ménard; Jean-Yves Blay; Christophe Borg; Stefan Michiels; François Ghiringhelli; Caroline Robert; Céline Nonn; Nathalie Chaput; Julien Taïeb; Nicolas F Delahaye; Caroline Flament; Jean-François Emile; Axel Le Cesne; Laurence Zitvogel
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

Review 4.  Chemokines and their role in tumor growth and metastasis.

Authors:  J M Wang; X Deng; W Gong; S Su
Journal:  J Immunol Methods       Date:  1998-11-01       Impact factor: 2.303

5.  Macrophage inflammatory protein-1 alpha expression in non-neoplastic and neoplastic lung tissue.

Authors:  T Konishi; H Okabe; H Katoh; Y Fujiyama; A Mori
Journal:  Virchows Arch       Date:  1996-05       Impact factor: 4.064

6.  Immunohistochemical characterization of intraepithelial and subepithelial mononuclear cells of the upper airways.

Authors:  F Graeme-Cook; A K Bhan; N L Harris
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

7.  Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.

Authors:  Andrea L Dewar; Antony C Cambareri; Andrew C W Zannettino; Bernadette L Miller; Kathleen V Doherty; Timothy P Hughes; A Bruce Lyons
Journal:  Blood       Date:  2005-01-06       Impact factor: 22.113

8.  Differential gene expression of chemokines in KRAS and BRAF mutated colorectal cell lines: role of cytokines.

Authors:  Sajjad Khan; Silke Cameron; Martina Blaschke; Federico Moriconi; Naila Naz; Ahmad Amanzada; Giuliano Ramadori; Ihtzaz Ahmed Malik
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

9.  Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects.

Authors:  Christophe Borg; Magali Terme; Julien Taïeb; Cédric Ménard; Caroline Flament; Caroline Robert; Koji Maruyama; Hiro Wakasugi; Eric Angevin; Kris Thielemans; Axel Le Cesne; Véronique Chung-Scott; Vladimir Lazar; Isabelle Tchou; Florent Crépineau; François Lemoine; Jacky Bernard; Jonhantan A Fletcher; Ali Turhan; Jean-Yves Blay; Alain Spatz; Jean-François Emile; Michael C Heinrich; Salah Mécheri; Thomas Tursz; Laurence Zitvogel
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

10.  A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

Authors:  Omid Hamid; Henrik Schmidt; Aviram Nissan; Laura Ridolfi; Steinar Aamdal; Johan Hansson; Michele Guida; David M Hyams; Henry Gómez; Lars Bastholt; Scott D Chasalow; David Berman
Journal:  J Transl Med       Date:  2011-11-28       Impact factor: 5.531

View more
  13 in total

Review 1.  Current status of immunotherapy for gastrointestinal stromal tumor.

Authors:  Y Tan; J C Trent; B A Wilky; D A Kerr; A E Rosenberg
Journal:  Cancer Gene Ther       Date:  2017-02-10       Impact factor: 5.987

2.  Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor.

Authors:  Gerardo A Vitiello; Timothy G Bowler; Mengyuan Liu; Benjamin D Medina; Jennifer Q Zhang; Nesteene J Param; Jennifer K Loo; Rachel L Goldfeder; Frederic Chibon; Ferdinand Rossi; Shan Zeng; Ronald P DeMatteo
Journal:  J Clin Invest       Date:  2019-02-14       Impact factor: 14.808

3.  Long-term adjuvant treatment of gastrointestinal stromal tumors (GIST) with imatinib-a comment and reflection on the PERSIST-5 study.

Authors:  Silke Cameron
Journal:  Transl Gastroenterol Hepatol       Date:  2018-03-14

4.  The KDM6A-SPARCL1 axis blocks metastasis and regulates the tumour microenvironment of gastrointestinal stromal tumours by inhibiting the nuclear translocation of p65.

Authors:  Chaoyong Shen; Luyin Han; Baike Liu; Guixiang Zhang; Zhaolun Cai; Xiaonan Yin; Yuan Yin; Zhixin Chen; Bo Zhang
Journal:  Br J Cancer       Date:  2022-02-08       Impact factor: 9.075

Review 5.  Synchronous of gastric adenocarcinoma and schwannoma: report of a case and review of literatures.

Authors:  Lian-He Yang; Jin-Ou Wang; Shuang Ma; Zhi Zhu; Jia-Xing Sun; Si-Lu Ding; Guang Li; Hong-Tao Xu; Liang Wang; Sun-Dong Dai; Yang Liu; Yuan Miao; Gui-Yang Jiang; Chui-Feng Fan; En-Hua Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

6.  Immune Cell Infiltration and the Expression of PD-1 and PD-L1 in Primary PDGFRA-Mutant Gastrointestinal Stromal Tumors.

Authors:  Xiangfei Sun; Jianyi Sun; Wei Yuan; Xiaodong Gao; Min Fu; Anwei Xue; He Li; Ping Shu; Yong Fang; Yingyong Hou; Kuntang Shen; Yihong Sun; Jing Qin; Xinyu Qin
Journal:  J Gastrointest Surg       Date:  2020-11-09       Impact factor: 3.452

Review 7.  Translating Knowledge About the Immune Microenvironment of Gastrointestinal Stromal Tumors into Effective Clinical Strategies.

Authors:  Jomjit Chantharasamee; Jacob J Adashek; Karlton Wong; Mark A Eckardt; Bartosz Chmielowski; Sarah Dry; Fritz C Eilber; Arun S Singh
Journal:  Curr Treat Options Oncol       Date:  2021-01-05

Review 8.  Parallel Aspects of the Microenvironment in Cancer and Autoimmune Disease.

Authors:  Michal A Rahat; Jivan Shakya
Journal:  Mediators Inflamm       Date:  2016-02-22       Impact factor: 4.711

9.  Phase I trial evaluating safety and efficacy of intratumorally administered inflammatory allogeneic dendritic cells (ilixadencel) in advanced gastrointestinal stromal tumors.

Authors:  Robin Fröbom; Erik Berglund; David Berglund; Inga-Lena Nilsson; Jan Åhlén; Karin von Sivers; Christina Linder-Stragliotto; Peter Suenaert; Alex Karlsson-Parra; Robert Bränström
Journal:  Cancer Immunol Immunother       Date:  2020-06-13       Impact factor: 6.968

10.  Tumor genotype, location, and malignant potential shape the immunogenicity of primary untreated gastrointestinal stromal tumors.

Authors:  Daniela Gasparotto; Marta Sbaraglia; Sabrina Rossi; Davide Baldazzi; Monica Brenca; Alessia Mondello; Federica Nardi; Dominga Racanelli; Matilde Cacciatore; Angelo Paolo Dei Tos; Roberta Maestro
Journal:  JCI Insight       Date:  2020-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.